Oneness Biotech (4743) reported revenue of NT$11.1 million for Oct 2026, +154.7% year on year and +97.2% from the previous month. Revenue for Jan–Oct 2026 was NT$107.9 million (+19.5% year on year).
In Oct 2026, it ranked No. 134 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$11.1 million | +154.7% | +97.2% |
| Sep 2026 | NT$5.6 million | -18.5% | -4.5% |
| Aug 2026 | NT$5.9 million | -39.4% | -31.9% |
| Jul 2026 | NT$8.7 million | -50.0% | -17.1% |
| Jun 2026 | NT$10.5 million | +26.5% | +34.5% |
| May 2026 | NT$7.8 million | +1.9% | -64.1% |
| Apr 2026 | NT$21.7 million | +101.8% | +50.7% |
| Mar 2026 | NT$14.4 million | +128.8% | +51.9% |
| Feb 2026 | NT$9.5 million | -15.9% | -25.9% |
| Jan 2026 | NT$12.8 million | +66.5% | -58.3% |
| Dec 2025 | NT$30.6 million | +169.8% | +273.1% |
| Nov 2025 | NT$8.2 million | -13.5% | +87.6% |
| Oct 2025 | NT$4.4 million | -58.6% | -36.9% |
| Sep 2025 | NT$6.9 million | -35.6% | -29.0% |
| Aug 2025 | NT$9.8 million | -11.3% | -43.8% |
| Jul 2025 | NT$17.4 million | +130.5% | +109.8% |
| Jun 2025 | NT$8.3 million | -32.1% | +8.3% |
| May 2025 | NT$7.6 million | +3.1% | -28.8% |
| Apr 2025 | NT$10.7 million | -9.1% | +70.8% |
| Mar 2025 | NT$6.3 million | -39.2% | -44.2% |
| Feb 2025 | NT$11.3 million | +78.8% | +46.6% |
| Jan 2025 | NT$7.7 million | -16.3% | -32.3% |
| Dec 2024 | NT$11.3 million | +37.1% | +19.6% |
| Nov 2024 | NT$9.5 million | +6.1% | -10.2% |
| Oct 2024 | NT$10.6 million | +25.1% | -1.8% |
Jan–Oct 2026 cumulative: NT$107.9 million (+19.5% YoY)
Other Biotech & Medical companies
Compare with peers: Oneness Biotech vs PEC / Oneness Biotech vs Lotus Pharm / Oneness Biotech vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本月營收增加,主係客戶需求增加。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16